Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Issue 3 (13th July 2011)

• Record Type: Journal Article
• Authors: Cullen, Garret; Bader, Caroline; Korzenik, Joshua R; Sands, Bruce E
• Is Part Of: Gut. Volume 61:Issue 3(2012)
• Page Start: 385
• Page End: 391
• Publication Date: 2011-07-13
• Subjects: Vaccination -- Crohn's disease -- ulcerative colitis -- inflammatory bowel disease -- immunosuppression -- influenzaimmunodeficiency -- dysplasia -- IBD clinical; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2011-300256
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Background: Influenza vaccination is recommended for patients with inflammatory bowel disease (IBD). The 2009 H1N1 influenza vaccine produced seroprotection rates of >85% in the general population but there are no data on the immunogenicity of the vaccine in patients with IBD. Methods: An observational prospective open-label study was conducted to examine the immunogenicity of the 2009 H1N1 influenza vaccine in 108 patients with IBD. Patient details, medications and disease activity were recorded. Pre- and post-vaccination haemagglutinin inhibition titres and geometric mean titres were measured. A functional assay of T lymphocyte activity was measured at vaccination in a subset of patients as an alternative measure of immunosuppression. Subjects were followed for 6 months post-vaccination. Results: Of 108 patients enrolled, 105 completed the study. The post-vaccination seroprotection rate was 50%. Immunosuppressed subjects had a lower rate of seroprotection than non-immunosuppressed subjects (44% vs 64%, p=0.06). The proportion with seroprotection was significantly lower in subjects on combination immunosuppression than in those receiving no immunosuppression (36% vs 64%, p=0.02). Patients receiving combined immunosuppression had a significantly lower fold increase in geometric mean titres than those on monotherapy immunosuppression (3.5 vs 11.5, p=0.03). An assay of T lymphocyte activity was performed in a subgroup of 48 subjects. Those with intermediate activity had lower seroprotection than those with high activity (28% vs 61%, p=0.02). The vaccine was well tolerated. Conclusions: Patients with IBD vaccinated with the 2009 H1N1 influenza vaccine had a low rate of seroprotection, particularly among those who were immunosuppressed. Although there is a need for studies of the clinical benefit of vaccines in this population, patients with IBD need to be aware of this reduced immunogenicity.